Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs)

Sergieva, Sonya; Robev, Bozhil; Dimcheva, Milena; Fakirova, Albena; Hristoskova, Radka

doi:10.5603/nmr.2016.0017

Cited by 15 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fusion SPECT-CT images improve image quality, show correct topography and morphological characteristics of metastatic lesions and provide exact differential diagnosis of the physiological from abnormal uncertain "hot" spots, thus increasing diagnostic accuracy of somatostatin-receptor SPECT studies [6][7][8]. Radionuclide targeting of somatostatin receptors for internal radiation therapy provides another therapeutic approach in advanced symptomatic non-operable MTC [8,10].…”

Section: Discussionmentioning

confidence: 99%

“…Radionuclide targeting of somatostatin receptors for internal radiation therapy provides another therapeutic approach in advanced symptomatic non-operable MTC [8,10].…”

Section: Discussionmentioning

confidence: 99%

“…Theranostics (therapy and diagnosis) using radiolabeled somatostatin analogues has proved to be a treatment method of choice in the individual management of neuroendocrine tumors overexpressed SSTR [8,11]. Peptide receptor radionuclide therapy (PRRT) using 177 Lu-labeled or 90 Y-labeled somatostatin analogues may have a significant clinical application in the management of MTC expressed SSTR established by SPECT-CT with 111 In-pentetreotide/ 99m Tc-Tektrotyd or PET-CT with 68 Ga-labeled somatostatin analogues [11,12].…”

Section: Discussionmentioning

confidence: 99%

“…SPECT-CT somatostatin receptor imaging with radiolabeled somatostatin analogues has been recommended for staging and followup of patients neuroendocrine tumors [5,8]. 99m Tc-Tektrotyd has high affinity to somatostatin receptors SSTR2 and lower to SSTR3 and SSTR5.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

SPECT-CT Modality for Imaging of Medullary Thyroid Cancer (MTC)

Sergieva¹,

Atanasova²,

Terziev³

2017

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Medullary thyroid cancer (MTC) is a neuroendocrine tumor that arises from the parafollicular Calcitonin-producing C-cells of the thyroid. Typically the MTC is an extremely slow-growing cancer; however, it has a tendency of spreading distant metastases fairly early. Systemic chemotherapy and external been radiotherapy have not shown to give a good MTC response. As of date radical thyroidectomy is the main method of choice for therapy. New compounds like tyrosine kinase inhibitors (TKIs) targeting signaling pathways may have a positive outcome and be of great clinical benefits in patients with advanced and metastatic MTC. Somatostatin receptor are over expressed in MTC and thus allows the use of radiolabeled somatostatin analogues for scintigraphic imaging before and after treatment for proper staging and follow-up of these patients. SPECT-CT is used to optimize somatostatin-receptor scintigraphic protocols for MTC imaging. We have presented a case report of a patient who underwent total thyroidectomy with bilateral lymphadenectomy in August 2006 due to the diagnosed MTC. This patient was treated by chemotherapy and surgery during the period between January/2007-December/2014 because of the recurrent disease. In December 2014 the calcitonin level reached 56 000 pg/ml; whole body scan with 740 MBq 99m Tc-EDDA/HYNIC-TOC, followed by target SPECT-CT showed a total disease progression with advanced metastatic dissemination into the body. The assigned therapy was with Caprelsa ® (Vandetanib) 300 mg/d orally which was initialized from March 2015 until present. In June 2016 a control SPECT-CT somatostatinreceptor scintigraphy with 740 MBq 99m Tc-Tektrotyd was performed from which was reported a partial disease response with a reduction of about 60% in size and a decrease in the number of metastatic lesions shown to correlated with the decreased calcitonin level up to 1560 pg/ml. It can be concluded that SPECT-CT with 99m TcTektrotyd has important clinical role for re-staging and follow-up of patients with recurrent and metastatic MTC after target therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Radionuclide targeting of somatostatin receptors for internal radiation therapy provides another therapeutic approach in advanced symptomatic non-operable MTC [8,10].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

SPECT-CT Modality for Imaging of Medullary Thyroid Cancer (MTC)

Sergieva¹,

Atanasova²,

Terziev³

2017

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

show abstract

“…In addition to initial staging patients, diphosphonate scintigraphy is widely employed to re-stage advance disease during or after treatment. 99m Tc-labeled hydrazinonicotinyl-Tyr3-octreotide (EDDA/HYNIC-TOC) is commonly used for the management of neuroendocrine tumors (NET) [10–12]. Although the 68 Ga-DOTA-somatostatin analogue PET/CT is now the recommended standard method for imaging, staging and restaging most types of NET [13,14], the 99m Tc-labeled platform represents a good alternative to Gallium-68 radiotracers where PET/CT or Gallium-68 generators are not available [15].…”

Section: Different Radioisotopes For Imagingmentioning

confidence: 99%

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Fernandes

Ferreira

Soares

et al. 2017

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.

show abstract